This clinical trial focuses on patients with Arterial Hypertension, a condition where blood pressure is higher than normal. The study will test whether adding a medication called Dapagliflozin, which belongs to a group of drugs known as SGLT2 inhibitors, to standard blood pressure treatment can help reduce heart and kidney problems in patients with high blood pressure.
The study will use Dapagliflozin film-coated tablets containing 10 milligrams of the medication, which will be taken by mouth once daily. Some participants will receive the active medication, while others will receive a placebo. The treatment period will last for 78 weeks, during which the effects of the medication on heart health and kidney function will be monitored.
The main purpose of this research is to determine if adding this medication to regular blood pressure treatment can lower the risk of serious heart-related events, such as heart attacks, strokes, and kidney problems. The study will also look at how well the medication controls blood pressure and its effects on overall health and quality of life.



Austria
Germany
Italy
Portugal
Slovenia
Spain